中医药抗肝纤维化疗效评价的探索

徐列明

doi:10.3969/j.issn.1001-5256.2017.05.006

中医药抗肝纤维化疗效评价的探索

DOI: 10.3969/j.issn.1001-5256.2017.05.006

徐列明

上海中医药大学附属曙光医院,上海中医药大学肝病研究所

详细信息

中图分类号: R259
计量
- 文章访问数: 2723
- HTML全文浏览量: 70
- PDF下载量: 493
- 被引次数: 0
出版历程
- 收稿日期: 2017-01-27
- 出版日期: 2017-05-20

An exploration of therapeutic evaluation of traditional Chinese medicine in treatment of hepatic fibrosis

Xu LieMing

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine & Institute of Hepatology, Shanghai University of Traditional Chinese Medicine

摘要

摘要: 我国在利用中成药治疗肝纤维化方面已走在国际前列。建议从抗肝纤维化的近期疗效、长期疗效和症状改善疗效3个方面开展评价,并介绍了笔者探索应用肝脏弹性测量值评价中成药抗纤维化的临床疗效,以5年生存率评价长期疗效,以及采用"中医证候评定量表"评价症状改善疗效的实践结果,显示出中成药扶正化瘀胶囊/片抗肝纤维化的临床疗效显著。建议配合血清学诊断模型,开展前瞻性的长期随访和对长期积累的大样本、大数据作分析,以完善抗肝纤维化疗效评价方法。
- 肝硬化 /
- 中成药 /
- 治疗结果
Abstract: China has become one of the leading counties in the world to treat hepatic fibrosis with Chinese patent drugs.The therapeutic effect of traditional Chinese medicine (TCM) should be evaluated from the aspects of short-term therapeutic effect, long-term therapeutic effect, and effect of relief of symptoms.This article introduces the results of our exploration of the application of liver stiffness measurement to evaluate therapeutic effect, five-year survival rate to assess long-term therapeutic effect, and a “TCM syndrome scale” to evaluate effect of relief of symptoms, suggesting that the Chinese patent drug Fuzheng Huayu capsules/tablets have a marked clinical effect in the treatment of hepatic fibrosis.It is recommended to use serological diagnostic models, conduct prospective studies with long-term follow-up, and analyze the samples and data accumulated over a long period of time, in order to perfect the methods for evaluating the outcome of hepatic fibrosis.
- liver cirrhosis /
- Chinese patent drugs /
- treatment outcome

HTML全文

参考文献(25)

[1]HU XQ, ZHANG JS.Liver biopsy-practice and concepts of pathological diagnosis of hepatic fibrosis[J].J Diagn Concepts Pract, 2005, 4 (1) :71-74, 79. (in Chinese) 胡锡琪, 张锦生.肝穿刺活检-肝纤维化的病理诊断实践与理论[J].诊断学理论与实践, 2005, 4 (1) :71-74, 79.

[2]ZHANG G, HU Y, LU LG.Opportunity and challenge for diagnosis and treatment of hepatic fi brosis[J].World Chin J Dig, 2015, 23 (36) :5743-5749. (in Chinese) 张国, 胡烨, 陆伦根.肝纤维化诊治机遇与挑战[J].世界华人消化杂志, 2015, 23 (36) :5743-5749.

[3]ZHENG M, CAI WM, WENG HL, et al.ROC curve in evaluation of serum fibrosis index for diagnosing hepatic fibrosis[J].Chin J Infect Dis, 2002, 20 (4) :225-228. (in Chinese) 郑敏, 蔡卫民, 翁红雷, 等.ROC曲线评价血清纤维化指标对诊断肝纤维化的价值[J].中华传染病杂志, 2002, 20 (4) :225-228.

[4]TAO J, PENG HQ, CAI WM, et al.Influence factors of serum fibrosis markers in liver fibrosis[J].World J Gastroenterol, 2003, 9 (11) :2497-2500.

[5]SHI YL, HE HL, WU XH, et al.The relationship between the levels of serum HA、LN、ⅣC and PⅢNP of chronic hepatitis and indexes of live fibrosis[J].Inter Med Health Guid News, 2006, 12 (8) :81-83. (in Chinese) 石亚玲, 何浩岚, 吴雪辉, 等.慢性乙型肝炎患者血清HA、LN、ⅣC及PⅢNP含量与肝纤维化程度的关系探讨[J].国际医药卫生导报, 2006, 12 (8) :81-83.

[6]LI X, ZHANG LX, CHEN YB, et al.Study on the correlation between serological indicators of hepatic fibrosis and PAPP and hepatic fibrosis[J].Chin Med Biotechnol, 2009, 4 (5) :350-354. (in Chinese) 李忻, 张立新, 陈亚宝, 等.血清肝纤维化指标及PAPP指数与肝纤维化的相关性研究[J].中国医药生物技术, 2009, 4 (5) :350-354.

[7]XUE YJ, YANG GR, ZHANG WJ, et al.Diagnostic value of detection of serum HA、LN、PCⅢ、CⅣfor liver fibrosis[J].Chin J Integr Tradit West Med Liver Dis, 2010, 20 (3) :178-179. (in Chinese) 薛永杰, 杨国嵘, 张文杰, 等.透明质酸、层粘连蛋白、Ⅲ型前胶原和Ⅳ型胶原血清学指标对肝硬化诊断的价值[J].中西医结合肝病杂志, 2010, 20 (3) :178-179.

[8]LIN LJ, XU LM.Whether the four serum markers of liver fibrosis have a reliable diagnostic value[J].Chin Hepatol, 2012, 17 (6) :433-435. (in Chinese) 林利静, 徐列明.肝纤维化四项血清标志物是否存在可信诊断价值[J].肝脏, 2012, 17 (6) :433-435.

[9]ZHANG YG, ZHAO SX, ZHOU GD, et al.Correlation of Fibro Touch and Fibro Scan with the stage of primary biliary cirrhosis[J].Chin JHepatol, 2016, 24 (12) :902-906. (in Chinese) 张玉果, 赵素贤, 周光德, 等.Fibro Touch、Fibro Scan与原发性胆汁性肝硬化分期的相关性分析[J].中华肝脏病杂志, 2016, 24 (12) :902-906.

[10]GE N, HE Q.Ultrasound elastography for evaluation of classification of liver fibrosis[J].J Clin Hepatol, 2016, 32 (12) :2379-2382. (in Chinese) 葛娜, 何茜.超声弹性成像对肝纤维化分级的评估[J].临床肝胆病杂志, 2016, 32 (12) :2379-2382.

[11]WELLS RG.The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis[J].J Clin Gastroenterol, 2005, 39 (4) :s158-s161.

[12]SANADA M, EBARA M, FUKUDA H, et al.Clinical evaluation of sonoelasticity measurement in liver using ultrasonic imaging of internal forced low frequency vibration[J].Ultrasound Med Biol, 2000, 26 (9) :1455-1460.

[13]VIZZUTTI F, ARENAL U, MARRA F, et al.Elastography for the non-invasive assessment of liver disease:limitation and future developments[J].Gut, 2009, 58 (2) :157-160.

[14]XU LM.Traditional Chinese medicine therapy and assessment of liver fibrosis[J].Drug Eval, 2007, 4 (4) :285-288. (in Chinese) 徐列明.肝纤维化中医药治疗和评价[J].药品评价, 2007, 4 (4) :285-288.

[15]LI ZJ, ZHANG XE, SU GQ, et al.Special project of basic research on traditional Chinese medicine theories in 973 Program Compilation of project achievements from 2005 to 2006[M].Beijing:China Press of Traditional Chinese Medicine, 2011:179. (in Chinese) 李振吉, 张先恩, 苏刚强, 等.973计划中医理论基础研究专项2005-2006年项目成果集[M].北京:中国中医药出版社, 2011:179.

[16]FRIEDMAN SL, BANSAL MB.Reversal of hepatic fibrosis-fact or fantasy?[J].Hepatolology, 2006, 43 (2) :s82-s88.

[17]LIN LJ, CHEN GF, GU HT, et al.Performance of Fibro Scan in evaluating the curative effects of traditional Chinese medicine on liver fibrosis[J].Chin J Hepatol, 2014, 22 (2) :113-117. (in Chinese) 林利静, 陈高峰, 顾宏图, 等.Fibro Scan评判中医药抗肝纤维化疗效的价值[J].中华肝脏病杂志, 2014, 22 (2) :113-117.

[18]SUN LD, ZHANG M, TANG Z.An analysis on prognosis in 289patients with decompensatory cirrhosis[J].Shandong Med J, 2009, 49 (32) :10-12. (in Chinese) 孙立东, 张玫, 汤哲.289例失代偿期肝硬化患者预后分析[J].山东医药, 2009, 49 (32) :10-12.

[19]SHI Y, SONG T, SHAN MJ.Clinical effect of Fuzheng Huayu capsules combined with tranexamic acid in treatment of chloasma[J].Chin J Dermato Venerol Integ Trad W Med, 2016, 15 (4) :239-240. (in Chinese) 时悦, 宋婷, 单敏洁.扶正化瘀胶囊联合氨甲环酸治疗黄褐斑的临床观察[J].中国中西医结合皮肤性病学杂志, 2016, 15 (4) :239-240.

[20]GUO XF, ZHU Q, LYU WH, et al.Primary application of chronic liver disease questionnaire in HBs Ag carriers[J].Jilin Med J, 2010, 31 (11) :1472-1474. (in Chinese) 郭新峰, 朱泉, 吕渭辉, 等.慢性肝病问卷在乙型肝炎病毒携带者中的初步试用[J].吉林医学, 2010, 31 (11) :1472-1474.

[21]ZHANG H, LIU P.A study on the thoughts and methods for quantitative research on TCM syndrome[J].Chin J Basic Med Tradit Chin Med, 2009, 15 (8) :574-576. (in Chinese) 张华, 刘平.中医证候量化研究的思路与方法探析[J].中国中医基础医学杂志, 2009, 15 (8) :574-576.

[22]WU CH, DENG QW, JI XS, et al.Preliminary use of the CLDQ in chronic hepatitis B patients[J].Chin J Clin Psychol, 2003, 11 (1) :60-62. (in Chinese) 吴创鸿, 邓启文, 纪晓抒, 等.慢性肝病问卷在慢性乙型肝炎患者中的试用[J].中国临床心理学杂志, 2003, 11 (1) :60-62.

[23]ZHANG H, LV H, HUANG PX, et al.Comparative study of TCMsyndrome scale for liver disease and chronic liver disease questionnaire based on assessment of posthepatitic cirrhosis[J].Evid Based Complement Alternat Med, 2012, 2012:496575.

[24]CHENG XJ, LU W, HOU W, et al.Diagnostic value of Fibro Test combined with Fibro Scan for liver fibrosis in patients with chronic hepatitis B[J].J Clin Hepatol, 2014, 30 (5) :424-427. (in Chinese) 程晓静, 陆伟, 侯伟, 等.Fibro Test联合Fibro Scan对慢性乙型肝炎肝纤维化的诊断价值[J].临床肝胆病杂志, 2014, 30 (5) :424-427.

[25]LEI CD, REN Y, ZHENG SJ, et al.Diagnostic value of the APRIindex for liver fibrosis in a Chinese patients population with chronic hepatitis C acquired from blood transfusion[J].J Clin Hepatol, 2013, 29 (5) :343-347. (in Chinese) 雷成多, 任艳, 郑素军, 等.APRI指数对定西地区感染HCV的供血员肝纤维化的诊断价值[J].临床肝胆病杂志, 2013, 29 (5) :343-347.

施引文献

资源附件(0)

访问统计